

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



CENTER FOR MEDICARE

DATE: August 26, 2024

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE plans

FROM: Vanessa S. Duran, Director
Medicare Drug Benefit and C & D Data Group

SUBJECT: CY 2025 September Formulary Enhancement Submission Window

CMS is offering a final CY 2025 formulary enhancement submission window prior to the start of the contract year. While Part D sponsors may enhance their formularies at any time, including prior to the start of the contract year, we are offering this additional window to allow another opportunity for plans to submit formulary enhancements so that the Medicare Plan Finder displays accurate and up-to-date formulary information during the Annual Election Period.

Enhancements include the addition of a Part D drug, the movement of a formulary drug to a lower cost-sharing tier, and the removal of utilization management requirements. Please note that we do not expect sponsors to make significant formulary enhancements during this window, as the formulary that was initially submitted to CMS for review was used to develop the Part D bid. Part D sponsors making immediate substitutions in accordance with 42 CFR § 423.120(e)(2)(i) at this time for their CY 2025 formularies must, under §423.120(f)(3), submit such changes during this window.

We remind Part D sponsors to ensure that the most current version of the approved formulary is posted on your website by October 15, 2024 in accordance with 42 CFR §§ 423.128 and 423.2265(c). This includes all changes made to your formulary during the CY 2025 September Formulary Enhancement Submission Window.

The submission window will be open between **12:00 a.m. EDT on September 16, 2024 and 5:00 p.m. EDT on September 18, 2024**. An updated CY 2025 formulary reference file will be available within the CY 2025 HPMS Formulary Submission Module by close of business on September 11, 2024.

If you have any questions regarding this formulary enhancement window, please email PartDFormularies@cms.hhs.gov.